Sarepta Therapeutics, Inc. - Common Stock (SRPT)

Historical Holders from Q1 2014 to Q1 2025

Symbol
SRPT on Nasdaq
CUSIP
803607100
Type / Class
Equity / Common Stock
Shares outstanding
95.7M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
87.8M
Holdings value
$10.7B
% of all portfolios
0.008%
Grand Portfolio weight change
+0%
Number of holders
461
Number of buys
207
Number of sells
-217
Average Value change %
0%
Average buys %
+0.002%
Average sells %
-0.003%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Sarepta Therapeutics, Inc. - Common Stock (SRPT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Capital International Investors 9.3% $887M 8.9M Capital International Investors Dec 31, 2024

Institutional Holders of Sarepta Therapeutics, Inc. - Common Stock (SRPT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 1.13M $72.3M +$38.5M $63.82 36
2024 Q4 87.8M $10.7B +$239M $121.59 461
2024 Q3 85.8M $10.7B -$609M $124.89 454
2024 Q2 88.8M $14B +$1.08B $158.00 484
2024 Q1 81.9M $10.6B +$177M $129.46 413
2023 Q4 79.5M $7.66B -$372M $96.43 382
2023 Q3 79.2M $9.6B +$172M $121.22 386
2023 Q2 80.1M $9.18B -$53.9M $114.52 394
2023 Q1 76.8M $10.6B -$58.8M $137.83 415
2022 Q4 78.2M $10.1B +$85.8M $129.58 400
2022 Q3 77.5M $8.56B +$599M $110.54 357
2022 Q2 71.6M $5.37B +$109M $74.96 305
2022 Q1 72.2M $5.64B +$61.5M $78.12 310
2021 Q4 70.9M $6.39B +$536M $90.05 319
2021 Q3 64.9M $6B +$135M $92.48 295
2021 Q2 64M $4.97B -$93.9M $77.74 315
2021 Q1 65.5M $4.88B -$732M $74.53 342
2020 Q4 70.2M $12B -$166M $170.49 424
2020 Q3 71.7M $10.1B -$330M $140.43 389
2020 Q2 73.5M $11.8B +$154M $160.34 395
2020 Q1 72.7M $7.11B -$31.7M $97.82 338
2019 Q4 72.9M $9.4B -$5.61M $129.04 374
2019 Q3 72.6M $5.47B -$253M $75.32 325
2019 Q2 71.2M $10.8B +$369M $151.95 354
2019 Q1 70.5M $8.41B +$283M $119.19 355
2018 Q4 68.1M $7.44B +$733M $109.13 322
2018 Q3 60.1M $9.7B +$262M $161.51 333
2018 Q2 59.8M $7.91B +$569M $132.18 307
2018 Q1 56.4M $4.17B +$184M $74.09 262
2017 Q4 55.2M $3.07B +$54.9M $55.64 245
2017 Q3 53.7M $2.44B +$525M $45.36 225
2017 Q2 42.6M $1.44B +$82.2M $33.71 182
2017 Q1 40.7M $1.21B +$219M $29.60 174
2016 Q4 39.4M $1.08B -$168M $27.43 174
2016 Q3 42.4M $2.6B +$579M $61.41 182
2016 Q2 34.6M $660M -$12.9M $19.07 142
2016 Q1 34.9M $681M +$86.3M $19.52 128
2015 Q4 28.5M $1.1B +$34.8M $38.58 146
2015 Q3 27.8M $891M +$36.3M $32.11 144
2015 Q2 26.2M $797M +$87.1M $30.43 125
2015 Q1 24.2M $321M -$7.61M $13.28 112
2014 Q4 24.5M $354M -$43.8M $14.47 117
2014 Q3 26M $548M -$18.9M $21.10 121
2014 Q2 26.6M $794M +$16.3M $29.79 125
2014 Q1 26.6M $639M -$12.2M $24.03 114